Frankfurt
03.10.25 | 08:06
0,973 Euro
+0,10 % +0,001
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15:09 | DIAMYD MEDICAL AB: Hong Kong grants precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1 diabetes | 1 | Cision News | ||
| 14:40 | Diamyd Medical AB (publ): Hong Kong grants precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1 diabetes | 29 | GlobeNewswire (Europe) | Diamyd Medical has been granted a patent in Hong Kong protecting the use of insulin-based antigens to treat individuals with type 1 diabetes carrying the HLA DR4-DQ8 genetic marker. The patent is valid... ► Artikel lesen | |
| 11.09. | DIAMYD MEDICAL AB: New analysis to be presented at EASD supports potential of Diamyd to delay the progression of Stage 3 Type 1 Diabetes | 2 | Cision News | ||
| 10.09. | DIAMYD MEDICAL AB: Eurasia to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1 diabetes | 2 | Cision News | ||
| 10.09. | Diamyd Medical AB (publ): Eurasia to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1 diabetes | 82 | GlobeNewswire (Europe) | The Eurasian Patent Office has informed Diamyd Medical that the patent application protecting the use of insulin-based antigens for the treatment of individuals with type 1 diabetes carrying the HLA... ► Artikel lesen | |
| 05.09. | DIAMYD MEDICAL AB: ASSET partnership, coordinated by Diamyd Medical, organizes 2[nd] annual Type 1 Diabetes screening conference | 1 | Cision News | ||
| 22.07. | DIAMYD MEDICAL AB: Diamyd Medical releases the full video recording from a panel discussion at the ADA meeting in June | 1 | Cision News | ||
| DIAMYD MEDICAL Aktie jetzt für 0€ handeln | |||||
| 25.06. | DIAMYD MEDICAL AB: Quarterly Report 3 24/25 | 2 | Cision News | ||
| 25.06. | Diamyd Medical AB (publ): Quarterly Report 3 24/25 | 147 | GlobeNewswire (Europe) | Precision Medicine for Autoimmune Diabetes
Aiming for Accelerated Market Approval
Autoimmune or Type-1 Diabetes (T1D) is a progressive disease, diagnosed as at least two antibodies to the insulin producing... ► Artikel lesen | |
| 16.06. | DIAMYD MEDICAL AB: Diamyd Medical to participate in two key US diabetes events | 11 | Cision News | ||
| 19.05. | Diamyd Medical AB (publ): Diamyd Medical appoints Niklas Axelsson as CFO | 154 | GlobeNewswire (Europe) | Niklas Axelsson has been appointed CFO of Diamyd Medical. He will assume his position in August and will also join the management team. Niklas Axelsson brings more than 25 years of experience across... ► Artikel lesen | |
| 15.05. | DIAMYD MEDICAL AB: Adjustment of the number of shares and share capital in Diamyd Medical, receives SEK 1.6 million more than previously communicated | 4 | Cision News | ||
| 05.05. | DIAMYD MEDICAL AB: Diamyd Medical has expanded the recently completed rights issue with a directed new issue of SEK 41.6 million | 8 | Cision News | ||
| 30.04. | DIAMYD MEDICAL AB: Diamyd Medical announces final outcome in oversubscribed rights issue: SEK 224 million | 3 | Cision News | ||
| 30.04. | DIAMYD MEDICAL AB: Diamyd Medical updates the preliminary outcome and will exercise the additional unit issue following the oversubscribed rights issue, raising approximately SEK 224 million | 2 | Cision News | ||
| 29.04. | DIAMYD MEDICAL AB: Diamyd Medical's rights issue has been preliminarily subscribed to 95 percent, thereby raising approximately SEK 198 million | 1 | Cision News | ||
| 28.04. | DIAMYD MEDICAL AB: Last day of the subscription period in Diamyd Medicals rights issue | 1 | Cision News | ||
| 28.04. | DIAMYD MEDICAL AB: Europe to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in autoimmune diabetes | 1 | Cision News | ||
| 25.04. | Diamyd Medical AB (publ): Diamyd Medical's pivotal Phase 3 Type 1 Diabetes trial clears second-to-last safety review ahead of early readout in March 2026 | 177 | GlobeNewswire (Europe) | The independent Data Safety Monitoring Board (DSMB) has completed its fifth scheduled safety review of Diamyd Medical's registrational Phase 3 trial, DIAGNODE-3, evaluating the precision medicine immunotherapy... ► Artikel lesen | |
| 22.04. | DIAMYD MEDICAL AB: Shareholders in Diamyd Medical, including the Chairman of the Board, have provided additional subscription commitments in the ongoing rights issue | 2 | Cision News |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 50,47 | +1,00 % | Novo Nordisk-Aktie: Das sieht gefährlich aus | Die Aktie des dänischen Pharmariesen Novo Nordisk steht an der Börse aktuell wieder deutlich unter Druck. Diese Nachrichten aus den USA belasten das Papier jetzt, und so kann es weitergehen. Negative... ► Artikel lesen | |
| ABBVIE | 201,00 | -0,50 % | NurExone stärkt IP-Portfolio und Positionierung im Zukunftsmarkt der Exosomen-Therapien | ||
| INNOCAN PHARMA | 11,360 | +9,02 % | Rallye gestartet! Kursgewinn mit Ansage?! | ||
| ABBOTT LABORATORIES | 115,14 | +1,46 % | Abbott's Esprit BTK Dissolvable Stent Approved By Health Canada | NORTH CHICAGO (dpa-AFX) - Abbott Laboratories (ABT) on Monday announced that Health Canada has approved its dissolvable stent, the Esprit BTK Everolimus Eluting Resorbable Scaffold System.The... ► Artikel lesen | |
| ARZNEIWERK AG VIDA | 0,460 | +43,75 % | EQS-HV: Arzneiwerk AG VIDA: Bekanntmachung der Einberufung zur Hauptversammlung am 04.09.2025 in Berlin mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG | EQS-News: Arzneiwerk AG VIDA
/ Bekanntmachung der Einberufung zur Hauptversammlung
Arzneiwerk AG VIDA: Bekanntmachung der Einberufung zur Hauptversammlung am 04.09.2025 in Berlin... ► Artikel lesen | |
| ZOETIS | 125,16 | +0,08 % | Zoetis: A Solid Investment in the Growing Pet Medicine Market? | ||
| CRESCO LABS | 1,224 | +0,58 % | Cresco Labs Inc. - 6-K, Report of foreign issuer | ||
| CSPC PHARMA | 1,075 | +1,08 % | CSPC PHARMA (01093): DISCLOSEABLE TRANSACTION - DEEMED DISPOSAL OF EQUITY INTEREST IN CSPC INNOVATION ARISING FROM THE PROPOSED LISTING OF THE H SHARES ... | ||
| TONIX PHARMACEUTICALS | 20,600 | -2,83 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access | Mr. Kamath brings more than 25 years of market access, pricing, and commercial operations experience to Tonix On August 15, 2025, the U.S. Food and Drug Administration approved Tonmya (cyclobenzaprine... ► Artikel lesen | |
| AMARIN | 13,600 | -5,56 % | Amarin Corporation plc: Amarin Reports Second Quarter 2025 Financial Results | -- European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 51,00 | -0,97 % | Nektar Therapeutics: Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025 | SAN FRANCISCO, Sept. 9, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it will present results from the ongoing REZOLVE-AD Phase... ► Artikel lesen | |
| WUXI BIOLOGICS | 4,687 | +0,30 % | WuXi Biologics-Aktie leicht im Plus (4,441 €) | Das Wertpapier von WuXi Biologics notiert heute fester. Das Papier kostete zuletzt 4,44 Euro. Ein Preisanstieg in Höhe von 17 Cent erfreut derzeit die Aktionäre von WuXi Biologics. Zur Stunde kostet... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 103,60 | +1,27 % | Piper Sandler Maintains Overweight on Axsome (AXSM), Sees Growth in AD-Agitation | ||
| JAGUAR HEALTH | 2,230 | +0,90 % | Jaguar Health, Inc.: FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease | The two programs are being conducted under separate Single-Patient Investigational New Drug (sIND) applications in the United States SAN FRANCISCO, CA / ACCESS Newswire / September 30, 2025 / Jaguar... ► Artikel lesen | |
| DAIICHI SANKYO | 21,510 | +3,91 % | Dividendenbekanntmachungen (29.09.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACADIAN TIMBER CORP CA0042721005 0,29 CAD 0,1777 EUR ACOM CO LTD JP3108600002 10 JPY 0,0572 EUR ADVANTEST CORPORATION JP3122400009 19... ► Artikel lesen |
DIAMYD MEDICAL AB gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 0,973 Euro und damit +0,10 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAMYD MEDICAL AB finden Sie auf Wallstreet Online.